CDX-0159
Phase 1Small molecule
CDX-0159 is one of 96 small molecule programs targeting Urticaria. It is currently in Phase 1.
3
Indications
5
Total Trials
0
Active Trials
95
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
61 competitors in Urticaria
#DrugCompanyPhaseTrials
1Fasenra
AstraZenecaApproved
Clarinex
OOrganon and Co
Approved
Xyzal
CChattem
Approved
Trexall
Alnylam PharmaceuticalsApproved
Neoral
NovartisApproved
Zyrtec
KKenvue Brands
Approved
Allegra
CChattem
Approved
Imuran
LLegacy Health System
Approved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Pletal
OtsukaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CDX-0159. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- CCelldex Therapeutics